CTX6ΔcreB displays the wild-type phenotype ( Fig. 1) confirming that CreBC hyperactivation is responsible for enhanced growth in the presence of these β-lactam antibiotics.
Microarray transcriptomics has previously revealed that six genes are upregulated >10-fold in CTX6 in a CreB-dependent manner (3) . The use of previously constructed deletion mutants of these genes in CTX6 (3) revealed that creD is the CreBC regulated gene responsible for enhanced growth of CTX6 in the presence of cefoxitin, as illustrated in figure 2 . Deletion of creD in the CTX6 background reduced the optical density of a culture at 180 min post addition of the drug to the same extent as deletion of creB or creC (p<0.005 for each).
It is possible to activate cre regulon gene expression by over-expressing the response regulator creB in an otherwise wild-type background strain. We did this, as previously, using an arabinose expression system (2) and found that it enhances growth in the presence of β-lactam antibiotics, even at antibiotic concentrations greater than the MIC. For example, with cefotaxime, the growth curve of MG1655 carrying a control plasmid shows the drug inhibiting growth, lysing cells and overwhelming the population, causing the optical density of the culture to reduce to basal levels (Fig. 3) . Carriage of a plasmid allowing creB over-expression does not affect the MIC -the drug still kills the population -but the growth curve is more pronounced. There is more growth prior to killing, as seen particularly at 120 min post cefotaxime treatment in figure 3 (p<0.01). Deletion of the CreBC regulated gene creD blocks the ability of CreB hyper-production to improve the growth of MG1655 (p<0.05 at 120 min post cefotaxime treatment [Fig 3] ) confirming a role for CreD over-production in this CreBC mediated β-lactam tolerance phenotype.
To see if the creC hyperactive mutation in CTX6 gives a fitness advantage relative to CTX6ΔcreB over repeated cycles of growth, pairwise competition experiments were performed over 4 days. In order to mark CTX6ΔcreB so that it could be quantified in a culture when mixed with CTX6, the derivative CTX6creB::Chl R was used. Here, creB has been disrupted by insertion of a chloramphenicol resistance gene rather than deleted as used in earlier experiments, though the effect on CreBC regulated gene expression is known to be identical (2). CTX6yieJ::Chl R (3) was used in parallel as a control to confirm that any change in fitness seen was specific to disruption of creB and not due to Chl R ; yieJ is not responsible for the growth enhancement phenotype of CTX6 (Fig. 2) .
To perform these experiments, initially, cultures of both strains to be competed were inoculated separately into LB and incubated for 24 h at 37°C with shaking at 160 rpm. Next, 5 µl of each culture was used to inoculate a separate flask containing 50 ml of DM25 minimal medium (4), which was prepared from Davis minimal medium (Difco, Oxford, UK) supplemented with glucose and thymine (25 mg.l -1 and 2
mg.l at the start of the day (density at the end of the previous day divided by 100 to take account of the dilution factor on subculture) and N1 is the density of the strain (cfu/ml) at the end of the day. The selection rate for a competition is therefore calculated as r = M1-M2, Where M1 relates to CTX6 and M2 relates to CTX6::Chl R .
For each competition (one mixed culture) there were four selection rate values, one for each day, and for each fitness cost experiment, 6 competitions were run. Hence for each competition between two strains, 24 r value datapoints are obtained.
Differences in these sets of r value data for different comparisons were assessed using an unpaired t-test with Welch's correction to assess the statistical significance of the differences observed.
In the absence of antibiotics, disruption of neither creB nor yieJ had any significant effect on the fitness of CTX6 (Table 2 ). However, in the presence of half the MICs of cefotaxime, cefoxitin or meropenem (AdooQ Bioscience), an approximately 15% per day reduction in relative fitness (W) was observed after disrupting creB (p<0.05 for all comparisons) though there was no significant effect of disrupting yieJ ( Table 2) .
We also performed competition experiments using ampicillin or ceftazidime (both from Sigma), but no significant effect of CreBC hyperactivation on fitness was seen (Table 2) . To put the observed changes in relative fitness into perspective: starting with a ratio of approximately 1:1 for the two competing strains, after 4 days of competition the ratio was approximately 10:1 in favour of the CreBC hyperactive strain in the presence of half the MIC of cefoxitin, cefotaxime or meropenem.
Conclusions

Antibiotic resistance is defined in terms of a minimum inhibitory concentration (MIC)
of an antibiotic measured following growth of a very dilute starting culture in the presence of that antibiotic. After a set period of incubation, the MIC is defined as the concentration of drug required to completely inhibit growth. If the MIC of a drug against a bacterial isolate is greater than a consensually defined breakpoint -based on clinical experience and pharmacokinentic/dynamic properties of the antibioticthe isolate is said to be resistant (6) . However, in vivo, antibiotic concentrations are dynamic, and there are periods when they are sub-MIC, so even susceptible bacteria can multiply before the drug concentration raises to overcome it. Whilst this does not, of itself, cause treatment failure, it might provide time for resistant mutants to emerge, or for symptoms to persist in the patient before a cure is established.
Because of this possibility, we are interested in mutations that confer growth enhancement in the presence of an antibiotic without necessarily altering the antibiotics' MIC. Such mutations are very difficult to identify in a population because, in contrast to resistant mutants, enhanced growth mutants are not amenable to easy selection in vitro. Accordingly, even if the growth-enhancing mutation were a highfrequency event, the proportion of a population displaying the growth enhancement phenotype would be so small it would essentially be invisible. This phenotype of enhanced growth in the presence of antibiotic is somewhat different from the muchdiscussed phenotype of "persistence", where bacteria reduce their metabolic activity and/or growth rate to escape from the lethal actions of antibiotics, which tend to only kill growing cells (7) . The persister phenotype is easier to select than the growth enhancement phenotype because the persister population reveals itself after removal of antibiotic (8); the enhanced growth phenotype population does not.
In this paper, we have identified a mechanism that confers growth enhancement in the presence of β-lactams, the most commonly prescribed antibiotics, in E. coli, one of the most commonly encountered human pathogens. The clinical relevance of this finding is unclear, but it is an interesting observation that activation of the production of CreD, an inner membrane protein of uncertain function, confers growth enhancement in the presence of β-lactams. Interestingly, CreBC shares significant sequence identity with the BlrAB two-component system in Aeromonas spp (9,10), which is activated in response to β-lactam challenge, and controls β-lactamase production and so confers β-lactam resistance (11) . Importantly, BlrAB also activates transcription of blrD, which is a homologue of E. coli creD (10) . Indeed, a similar two component system, CreBC/BlrAB in Pseudomonas aeruginosa is also activated during β-lactam challenge (12, 13) , and whilst it does not control β-lactamase production, it does control transcription of the creD homologue in this species (12, 13) . It is therefore striking, that CreBC activation in E. coli enhances growth in the presence of β-lactams. This speaks to a common function for the CreD/BlrD proteins in these varied species of gamma-proteobacteria. Optical density of an LB culture was measured at 600 nm every hour following subculture and addition of cefotaxime (time zero) used at half its MIC against E. coli MG1655. Arabinose (0.2 % w/v) was added in all growth media to stimulate CreB production from the pUB6073 (pBAD(creB)) plasmid as used in (2) . Data represent means plus/minus standard error of the mean, n=3 after 180 mins post incubation. 
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